Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With data in hand showing RAD001 (everolimus) doubled progression-free survival in metastatic kidney cancer, Novartis is accelerating its submission schedule and plans to file for the indication by July for a possible 2009 launch of its mTOR inhibitor for oncology

You may also be interested in...

Novartis Oncology Pipeline Has Lucky 13 Clinical Candidates

Novartis Institute for Biomedical Research's six-year-old mechanism-based research model is cranking out targeted cancer therapeutics, with three new molecules headed for the clinic by the end of 2008

Novartis Everolimus Oral Dosing May Offer Advantages Over Wyeth's Torisel

Novartis halts Phase III study of the mTOR inhibitor early after everolimus shows better progression-free survival than placebo.

Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?

Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts